言語を選択

TRAIL R2

TRAIL R2 詳細

英語名	Tumor necrosis factor receptor superfamily member 10B	市販薬剤の数	1
治験薬の数	10	ターゲットの別称	Tumor necrosis factor receptor superfamily member 10B，CD262，DR5，KILLER，TRAILR2，Death receptor 5，TRAIL-R2，UNQ160/PRO186，TNFRSF10B，TNF Receptor Superfamily Member 10b，TNF-Related Apoptosis-Inducing Ligand Receptor 2，TRICK2，ZTNFR9，P53-Regulated DNA Damage-Inducible Cell Death Receptor(Killer)，Tumor Necrosis Factor Receptor-Like Protein ZTNFR9，Death Domain Containing Receptor For TRAIL/Apo-2L，Apoptosis Inducing Protein TRICK2A/2B，Apoptosis Inducing Receptor TRAIL-R2，Cytotoxic TRAIL Receptor-2，Fas-Like Protein，TRAIL Receptor 2，CD262 Antigen，KILLER/DR5，TRICK2A，TRICK2B，TRICKB，Tumor Necrosis Factor Receptor Superfamily， Member 10b
研究＆開発段階	Approved

英語名	Tumor necrosis factor receptor superfamily member 10B
ターゲットの別称	Tumor necrosis factor receptor superfamily member 10B，CD262，DR5，KILLER，TRAILR2，Death receptor 5，TRAIL-R2，UNQ160/PRO186，TNFRSF10B，TNF Receptor Superfamily Member 10b，TNF-Related Apoptosis-Inducing Ligand Receptor 2，TRICK2，ZTNFR9，P53-Regulated DNA Damage-Inducible Cell Death Receptor(Killer)，Tumor Necrosis Factor Receptor-Like Protein ZTNFR9，Death Domain Containing Receptor For TRAIL/Apo-2L，Apoptosis Inducing Protein TRICK2A/2B，Apoptosis Inducing Receptor TRAIL-R2，Cytotoxic TRAIL Receptor-2，Fas-Like Protein，TRAIL Receptor 2，CD262 Antigen，KILLER/DR5，TRICK2A，TRICK2B，TRICKB，Tumor Necrosis Factor Receptor Superfamily， Member 10b
市販薬剤の数	1
治験薬の数	10
研究＆開発段階	Approved

TRAIL R2 製品リスト

属性
Protein (6)
製品ライブラリ
オンライン (6)
種
Human (4)Mouse (1)Cynomolgus (1)
タグ
His Tag (4)Fc Tag (1)His Tag & Avi Tag (1)
マーカー
Unconjugated (4)Biotin-labeled (1)FITC Labeled (1)

製品番号	種	発現システム	製品説明
HOT TR2-H5229	Human	HEK293	Human TRAIL R2 / DR5 / TNFRSF10B Protein, His Tag, low endotoxin
HOT TR2-H5255	Human	HEK293	Human TRAIL R2 / DR5 / TNFRSF10B Protein, Fc Tag, low endotoxin
HOT TR2-H82E6	Human	HEK293	Biotinylated Human TRAIL R2 / DR5 / TNFRSF10B Protein, Avitag™,His Tag (MALS verified)
TR2-HF223	Human	HEK293	FITC-Labeled Human TRAIL R2 / DR5 / TNFRSF10B Protein, His Tag
TR2-M52H5	Mouse	HEK293	Mouse TRAIL R2 / DR5 / TNFRSF10B Protein, His Tag
TR2-C52H7	Cynomolgus	HEK293	Cynomolgus TRAIL R2 / DR5 / TNFRSF10B Protein, His Tag (MALS verified)

総数量6

TRAIL R2バックグランド

Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) is also known as TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2), Death receptor 5 (DR5), CD262, KILLER, is a member of the TNF-receptor superfamily, and contains an intracellular death domain. TNFRSF10B / DR-5 is widely expressed in adult and fetal tissues; very highly expressed in tumor cell lines. TRAILR2 / CD262 / DR5 is the receptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADD (a death domain containing adaptor protein) of TRAIL-R2 / TNFRSF10B recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. CD262 / DR5 Promotes the activation of NF-kappa-B. DR5 is essential for ER stress-induced apoptosis and is regulated by p53/TP53.

TRAIL R2分子の別称

TNFRSF10B,TRAILR2,TRAIL-R2,CD262,DR5,KILLER,TRICK2,ZTNFR9,TRICKB

治験薬に関する情報

英語名	研究コード	研究開発ステージ	会社	適応症	臨床試験
Dulanermin (Shanghai GeBaiDe)		Phase 3 Clinical	Shanghai Gebaide Biotechnology Co Ltd	Carcinoma, Non-Small-Cell Lung	詳細
Recombinant human tumor necrosis factor-related apoptosis-inducing ligand (Shenzhen Xinpeng Biotech)		Phase 3 Clinical	Shenzhen Sinobioway Xinpeng Biomedicine Co Ltd	Neoplasms	詳細
TLY-012	TLY-012	Phase 1 Clinical	Theraly Fibrosis	Fibrosis; Liver Cirrhosis; Pancreatitis; Pancreatitis, Chronic; Scleroderma, Systemic	詳細
BI-905711	BI-905711	Phase 1 Clinical	Boehringer Ingelheim International Gmbh	Cholangiocarcinoma; Gastrointestinal Neoplasms; Pancreatic Neoplasms	詳細
Recombinant anti-human DR5 monoclonal antibody (Lonn Ryonn Pharma)	CTB-006	Phase 1 Clinical	Beijing Tongwei Shidai Shengwu Jishu Youxian Gongsi, Lonn Ryonn Pharma Ltd	Solid tumours	詳細
Ozekibart	JCT-205; INBRX-109	Phase 1 Clinical	Inhibrx Inc	Adenocarcinoma	詳細
TRAILR2/CDH3 bispecific antibody (Boehringer Ingelheim)		Phase 1 Clinical	Boehringer Ingelheim International Gmbh	Neoplasms	詳細
RC-248	RC-248; RC248	Phase 1 Clinical		Solid tumours	詳細
IBI-3004	IBI-3004; IBI3004	Phase 1 Clinical		Colorectal Neoplasms; Solid tumours	詳細
Oba-01	Oba-01; Oba01	Phase 1 Clinical	Yantai Heyuanaidisi Biomedical Technology Co Ltd	Carcinoma, Non-Small-Cell Lung	詳細

市販薬剤に関する情報

英語名	研究コード	研究開発ステージ	会社	オリジナル製品名	最初に承認をした国	最初の適応症	最初に承認を受けた会社	承認された日付	適応症	臨床試験
Aponermin		Approved	Beijing Shadong Biotech Co Ltd	沙艾特, Shaite	Mainland China	Multiple Myeloma	Wuhan Hiteck Biological Pharma Co Ltd	2023-11-02	Multiple Myeloma	詳細